Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Stephen J. Moore et al.|Molecular Cancer Therapeutics|2022Cited by 35
Abstract B116: Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphoma models and for tolerability in nonhuman primatesShweta Singh, Michael Kavanaugh, Laura Serwer et al.|Molecular Cancer Therapeutics|2018Cited by 5
Supplementary Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Laura Serwer et al.|Unknown|2023Cited by 0
Supplementary Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Laura Serwer et al.|Unknown|2023Cited by 0
Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Laura Serwer et al.|Unknown|2023Cited by 0